IVF Booster Offered in Canada But Not US
By Alison Motluk,
Canadian Medical Association Journal
| 01. 14. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
A new fertility treatment that purports to help older women get pregnant by boosting the energy in their eggs is now being offered in Toronto, but nowhere else in North America. A trial in the US was voluntarily suspended after the Food and Drug Administration suggested the treatment may be considered an "investigational new drug" requiring approval. In Canada, it may fall outside regulation, though Health Canada has not made any formal response to date.
The treatment, called Augment, involves extracting mitochondria, a cell's energy supply, from a woman's own ovarian stem cells and injecting them into her eggs during in vitro fertilization. In December 2014, OvaScience, the US-based company that developed Augment, announced that the treatment would be offered commercially. No clinical data on efficacy were provided, though they noted that 150 women had been enrolled in experimental trials at four sites worldwide. These include the Toronto Centre for Advanced Reproductive Technology (TCART) and clinics in London, Istanbul and Dubai. Company Chief Executive Officer Michelle Dipp said they expected Augment would be used in approximately 1000 paying patients in 2015....
Related Articles
By Dr. Coco Newton, Progress Educational Trust | 03.30.2026
Have you ever wondered what it means to have dozens of half-siblings across the world – or to never know where half of your genetic identity comes from? A recent episode of Zembla explores the human consequences of the global...
By Marcelo Jauregui-Volpe, Wired | 04.24.2026
Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.
One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers...
By Alexandre Piquard, Le Monde [cites Katie Hasson] | 04.27.2026
"Si on en prouve la sûreté, nous croyons que l’édition préventive du génome pourrait être l’une des technologies de santé les plus importantes du siècle. » Lucas Harrington explique ainsi le but de son entreprise Preventive : créer des bébés génétiquement modifiés...
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...